Chugai Pharmaceutical Co., Ltd. (CHGCF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Chuo, Japan. The current CEO is Osamu Okuda.
CHGCF has IPO date of 2012-08-03, 5,026 full-time employees, listed on the Other OTC, a market capitalization of $90.63B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacture, and sale of medicines globally. The company maintains a diverse portfolio spanning oncology, immunology, hematology, ophthalmology, and other therapeutic areas, with established products including Tecentriq, Herceptin, Avastin, Rituxan, and Tamiflu. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances within the Roche Group and conducts collaborative research with academic institutions to advance its pipeline of development candidates. Founded in 1925 and headquartered in Chuo, Japan, the company continues to expand its international presence across multiple disease indications.
